Clinical trial NCT03429738: Single-Dose Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride Tablets
Official title: A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride 200 mg/30 mg Tablets Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pain, Head
Pain, Acute
Pain, Back
Fever
Keywords: Ibuprofen
phase-I-study
pharmacokinetic
combination therapy
bioavailability
bioequivalence
pseudoephedrine hydrochloride
Lead sponsor: Institut für Pharmakologie und Präventive Medizin
Sponsor class: NETWORK
Collaborators: name: Pharma Medica Research, Inc.
First posted: 2018-02-12
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: open-label, single-dose, randomized, two-period, two-treatment, twosequence, crossover, comparative bioavailability study.
Primary purpose: TREATMENT

Brief summary: Evaluation of the comparative bioavailability between two oral formulations containing ibuprofen 200 mg and pseudoephedrine 30 mg after a single dose in healthy subjects under fasting conditions.

Detailed description: Ibuprofen is one of the most often used non steroidal antiinflammatory drug (NSAR) in the management of mild to moderate pain and inflammation. Combined with the sympathomimetic pseudoephedrine as decongestant it is widely used in colds or fever. The purpose of this phase-I-study was to evaluate the comparative bioavailability between a combination of 200 mg ibuprofen and 30 mg pseudoephedrine film-coated tablets to the reference formulation RhinAdvil Rhume® 200 mg/30 mg (Wyeth Santé Familiale, France).

Eligibility criteria: Inclusion Criteria:

1. Healthy, non-smoking, male and female subjects, 18 years of age or older.
2. BMI ≥ 18.5 and 30.0 kg/m2
3. No clinically significant findings in vital signs measurements.
4. No clinically significant abnormal laboratory values.
5. No clinically significant findings in a 12-lead electrocardiogram (ECG).
6. No significant diseases.
7. Willing to use an acceptable, effective method of contraception.
8. Be informed of the nature of the study and give written consent prior to any study procedure.
9. Have no clinically significant findings from a physical examination.

Exclusion Criteria:

1. Known history or presence of any clinically significant medical condition.
2. Known or suspected carcinoma.
3. History or presence of ulcerative colitis, diverticulosis, Crohn's disease, or gastrointestinal ulcer, perforation, or haemorrhage.
4. Known history or presence of auto-immune disorders, gastrointestinal toxicity, or a risk of gastrointestinal bleeding or gastrointestinal tract irritation.
5. Known history or presence of cardiovascular disease, heart failure, tachycardia, hypertension, angina pectoris, hyperthyroidism, psychosis, seizures, risk of urinary retention, diabetes, phaeochromocytoma, closed angle glaucoma, chronic rhinitis, or prostatic enlargement.
6. Known history or presence of angioedema.
7. Known history or presence of galactose or fructose intolerance, sucraseisomaltase insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose malabsorption syndrome.
8. Known history of severe skin reactions (e.g. exfoliative dermatitis, SJS, and TEN).
9. Known history or presence of bronchial asthma or allergic disease resulting in bronchospasm.
10. Presence of hepatic or renal dysfunction.
11. Presence of clinically significant gastrointestinal disease or history of malabsorption within the last year.
12. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption.
13. History of drug or alcohol addiction requiring treatment.
14. History of gastrointestinal bleeding or perforation when previously taking NSAIDs.
15. Positive test result for HIV, Hepatitis B surface antigen or Hepatitis C antibody.
16. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines, cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone and benzodiazepines) or urine cotinine.
17. Difficulty fasting or consuming standard meals.
18. Does not tolerate venipuncture.
19. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
20. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
21. Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.
22. Donation or loss of whole blood (including clinical trials):

    * 50 mL and ≤ 499 mL within 30 days prior to drug administration
    * 500 mL within 56 days prior to drug administration.
23. Females who:

    Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to dosing; Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration; Are pregnant (serum hCG consistent with pregnancy); or Are lactating.
24. Have had a tattoo or body piercing within 30 days prior to drug administration.
25. Known history or presence of hypersensitivity or idiosyncratic reaction to ibuprofen, pseudoephedrine, NSAIDs, or any other drug substances with similar activity or any of the excipients in the drug products
26. Use of drugs in the phenethylamine and amphetamine chemical classes within 14 days prior to drug administration.
27. Use of NSAIDs (including cyclo-oxygenase-2 selective inhibitors) aspirin, corticosteroids, anticoagulants, selective serotonin-reuptake inhibitors, antihypertensives, diuretics, cardiac glycosides, lithium, methotrexate, cyclosporin, mifepristone, tacrolimus, zidovudine, linezolid, dopaminergic alkaloids, quinolone antibiotics, terpene derivatives, clobutinol, atropine, local anaesthetics, MAO inhibitors, vasoconstrictors, alpha sympathomimetic drugs, or anti-platelet agents within 30 days prior to drug administration.
28. Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to drug administration. (e.g. barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole, antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines).

Primary outcomes:
measure: AUC(0-t) (area under the analyte concentration versus time curve) of ibuprofen and pseudoephedrine, respectively
timeFrame: 7 days (± 3 hours)
measure: maximum serum concentration of ibuprofen and pseudoephedrine, respectively
timeFrame: 7 days (± 3 hours)
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Pharma Medica Research Inc.
state: Ontario
Study officials:
affiliation: Pharma Medica Research, Inc.
name: Latifa Yamlahi, MD
role: STUDY_DIRECTOR
References: